← Back to Pipeline

NextGen VP

IntroCool
Check size: TBDContacts: Deborah ChuLast contact: 2026-02-05
Next step: Keep me posted — no active process

Meetings

1
2026-02-05Meeting: NextGen VP

Informational call initiated by Thomas's cold outreach. Deborah invests in digital health at pre-seed/seed. She was analytical and somewhat skeptical throughout — pushed hard on differentiation, defensibility, vision clarity, and whether this is a tech company or consulting firm. Her main feedback: the pitch needs a clearer end-state vision and the deep-vs-broad strategy needs to be resolved. She shared useful market intel (Fourier Health in portfolio, Lumara Health and Logical Health as comps). Ended with standard "keep me posted, potentially a fit" — lukewarm. More valuable as market intelligence and pitch feedback than as an active investor lead.

Meeting: NextGen VP

Date: 2026-02-05 Attendees: Thomas Startz, Michael Yuan, Deborah Chu (NextGen VP) Type: Cold outreach / Intro + market color Duration: ~31 min Note: Transcript labels her "Deborah Chu" but meeting invite says "Deborah Chu" — may be a transcript error.

Context from Michael: "The texture of the call was quite awkward. Don't overindex on this one, but it is relevant as they are a VC."


Summary

Informational call initiated by Thomas's cold outreach. Deborah invests in digital health at pre-seed/seed. She was analytical and somewhat skeptical throughout — pushed hard on differentiation, defensibility, vision clarity, and whether this is a tech company or consulting firm. Her main feedback: the pitch needs a clearer end-state vision and the deep-vs-broad strategy needs to be resolved. She shared useful market intel (Fourier Health in portfolio, Lumara Health and Logical Health as comps). Ended with standard "keep me posted, potentially a fit" — lukewarm. More valuable as market intelligence and pitch feedback than as an active investor lead.


Questions Asked

#Question (verbatim/near-verbatim)TopicAnswer QualityNotes
1[Opening market color] "It's been hard to differentiate... underlying models are the same... hard to find things that are super differentiated and long term defensible"Competition / MoatN/ANot a question — she was framing her skepticism. Important context for everything that followed.
2"Are you positioning this more as a Palantir type model? Do you envision selling it to other payers with a forward deploy model, or embedding more deeply with the first two customers?"Business Model / StrategydecentThomas said both — deploy core product broadly + go deeper with existing. But she was probing for a choice and didn't get one.
3"Why and how did you decide to do [UM] first?"Market / StrategystrongResearch, conferences, talked to nurses, repeatable text analysis, financial swing ($2-5K/case), complex space no one's in. Good answer.
4"What has been or what do you expect to be your go-to-market approach?"GTMdecentFounder-led, Wharton relationships, conferences, top-down C-suite + bottom-up nurse hire. Honest but standard.
5"So you guys are looking to raise a seed?"FundraisedecentConfirmed. Mentioned capacity constraint with more clients.
6"What's the long term vision? What do you ultimately want to get to?"VisiondecentReal-time payer-provider integration, eliminate payment delays, every payer with visibility into every patient. Ambitious but she pushed for more specificity.
7"Does the product and contract values justify the initial [deployment] investment? Is there a roadmap to decreasing services upfront or enabling the customer to do more themselves? Or are we investing in a tech-enabled consulting firm long term?"Scalability / Business ModelweakThomas: "We're still figuring this out too. The clients are figuring out how to pay for these things as well." Honest but this is the answer that most undermines confidence.
8"What are the hypotheses that you are hoping to test?"Vision / StrategydecentThis was coaching, not a question. Thomas pivoted to: payer pressure hypothesis, United's cost cuts, utilization going up. Landed OK but felt improvised.

Concerns Raised

  • Differentiation is hard — She opened with this. "Underlying models are the same... people try to make arguments around being embedded in workflows... hard to find things that are super differentiated." This framed her entire evaluation.

  • Vision clarity — "If you're going to raise venture dollars, you need a pretty clear vision of the end state and a strong opinion on the direction the market is headed." She explicitly said the pitch needs more clarity on deep vs. broad.

  • Consulting firm risk — "Are we just investing in a tech-enabled consulting firm long term?" Same scalability concern as Refract, but stated more bluntly.

  • "Still figuring it out" — Thomas said this about pricing/business model. She was polite about it but it's clearly a yellow flag.

  • Moat question echoed back — Thomas himself raised the moat issue ("what's the defensibility if these products are so cross-applicable?"). This was honest but may have planted more doubt than confidence.


What Resonated

  • FDE/deployment model generally — "This notion of getting in there with your customers and deploying the product... most VCs are generally fairly comfortable with and favorable to." Validated the approach conceptually.

  • UM wedge choice — Seemed to accept the reasoning. Didn't push back on why UM specifically.

  • Payer pressure hypothesis — When Thomas articulated it crisply at the end ("payers will realize what United realized"), she said "yeah, yeah, cool" — most engaged she was.

  • Contract value justification — She assumed "six, seven figure contracts" for this type of work. Validates the revenue potential of the FDE model.


Our Commitments

None.

Their Next Steps

  • "Keep me posted... happy to take a look as you progress further. Potentially a fit for our stage and sector focus." — Standard lukewarm VC sign-off, not a commitment to next steps.

Investor Insights

Firm profile:

  • NextGen VP — pre-seed and seed, digital health focus
  • Deborah spends a lot of time in digital health investing

What they care about:

  • Differentiation and long-term defensibility (her #1 lens)
  • Clear vision / end state
  • Scalable business model (not just consulting)
  • Hypothesis-driven approach at seed stage

Portfolio comps:

  • Fourier Health — AI medical record summarization, customized for specific use cases, human in the loop. Mostly health systems. Transition of care, pre-visit summaries. Long sales cycles but sticky contracts.

Market intel shared:

  • Lumara Health — raising $1.5M pre-seed. Orchestration/knowledge layer for AI agents in healthcare. Benefits navigation + triage automation. Working with CareFirst (TPA), LOI with large East Coast Blues plan (likely CareFirst). Still building product.
  • Logical Health — payer member engagement. POC with large European insurer. Pre-seed stage.
  • General view: lots of AI healthcare activity, hard to differentiate, same underlying models. Member engagement side is where she's seen most payer-focused activity.

Pitch feedback (valuable coaching):

  1. Need clearer end-state vision — "strong opinion on the direction the market is headed"
  2. Deep vs. broad needs to be resolved — are you going deeper with 2 clients or broader across many?
  3. Frame it as hypotheses to test at seed stage — not certainties
  4. The "still figuring it out" answer on business model is a risk

Interesting Moments

Thomas raising the moat problem himself — "What's the defensibility if these products are so cross-applicable? It can't be that hard to build." Honest and thoughtful but potentially self-defeating in a pitch context. Better to acknowledge it briefly and pivot to the answer, not dwell on the problem.

Deborah's systems integrator analogy — "In the early days of software, the systems integrator played a very large role. I think there's a version of that in AI." She's seeing this pattern across deals. Worth understanding whether this is a compliment or a concern — VCs may view "next-gen SI" as a services business, not a venture-scale outcome.

"Had to jump to another call" — Cut off at 31 min. She wasn't compelled to extend. Contrast with Primary Ventures (Hannah stayed engaged despite being exhausted) and Refract (offered portfolio intros).

Call dynamic — Thomas carried the narrative, Michael contributed targeted points. Standard dynamic for this team — Thomas leads the story, Michael grounds it with specifics. The awkward texture of this particular call was more about the investor dynamic than the team dynamic.


Raw Transcript

[See above — ~31 minutes, Feb 5 2026]

Top Concern

Differentiation + vision clarity

Overview

  • Stage focus: Pre-seed and seed
  • Check size: TBD
  • Healthcare thesis: Digital health broadly. Skeptical of differentiation in AI healthcare — sees same underlying models, hard to find long-term defensible businesses. Interested in hypothesis-driven founders.
  • Key people: Deborah Chu (investor, digital health focus)

Relationship History

DateTypeNotes
2026-02-05Intro (cold outreach by Thomas)Informational/market color call. Skeptical but engaged. Shared useful intel (Fourier Health, Lumara, Logical Health). Feedback: need clearer vision, resolve deep vs. broad. Lukewarm close.

Status

  • Current stage: Intro / Informational — no active process
  • Next step: "Keep me posted" — ball is in our court if/when we have more traction or clarity
  • Temperature: Cool (polite but not excited)

What They Care About

  • Long-term defensibility and differentiation (her #1 concern)
  • Clear end-state vision with strong market opinion
  • Scalable business model, not tech-enabled consulting
  • Hypothesis-driven approach at seed

Concerns to Address

  • Differentiation — she doesn't see it yet in AI healthcare broadly
  • Vision clarity — felt the pitch was still exploring, not asserting
  • Business model uncertainty — "still figuring it out" was a yellow flag
  • Consulting vs. tech company — explicitly asked

Materials Sent

  • Nothing sent — she looked at website and some written materials beforehand

Notes

  • Cold outreach by Thomas — not inbound interest. Changes the dynamic.
  • Awkward call texture per Michael. Don't overindex.
  • Most valuable as market intelligence and pitch feedback source, not as active investor lead.
  • Portfolio comp Fourier Health is worth understanding — AI medical record summarization for health systems. Similar space.
  • Market intel on Lumara Health (CareFirst, pre-seed, $1.5M) and Logical Health (European insurer POC) useful for competitive awareness.
  • Her "systems integrator" analogy is worth sitting with — is that how VCs will categorize us? If so, need to differentiate from that framing.

Daisy

v1

What do you need?

I can pull up the fundraise pipeline, CRM accounts, hot board, meeting notes — anything in the OS.

Sonnet · read-only